---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-020116"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:44:14.956833+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AcelRx Q2 net income $70.7M on $84.1M debt gain; revenue $0.6M

## Summary
- Net income of $70.7M ($0.48 diluted EPS) vs net loss of $9.9M in Q2 2021, driven by $84.1M gain on extinguishment of royalty monetization liability.
- Revenue $0.6M; commercial ex-DoD unit sales up 133% YoY; total DSUVIA units 10,600.
- Realigned cost structure reducing headcount ~40%, generating expected annual savings of $9M.
- Cash and short-term investments $27.9M as of June 30, 2022; 983 DSUVIA formulary approvals achieved.
- Niyad supply chain progress; targeting Emergency Use Authorization in 2023; DZUVEO EU launch on track for Q3.

## SEC filing metadata
- accession: 0001437749-22-020116
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774922020116/0001437749-22-020116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774922020116/acrx20220810_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-020116
- JSON: https://secwatch.observer/filing/0001437749-22-020116.json
- Plain text: https://secwatch.observer/filing/0001437749-22-020116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.